Dr. Alexander Fosså：Phase II waveLINE-004 Study of ROR1-ADC Treatment for R/R DLBCL
On the 17th International Conference on Malignant Lymphoma (ICML), Dr. Alexander Fosså from Oslo University Hospital presented the results of the Zilovertamab vedotin (MK-2140) treatment for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), a Phase II open-label, waveLINE-004 study. Oncology Frontier interviewed Dr. Fosså at the conference.